Total Payments
$2,545
2024 Payments
$260.87
Companies
11
Transactions
75
Medicare Patients
1,249
Medicare Billing
$290,281
Payment Breakdown by Category
Education$1,557 (61.2%)
Food & Beverage$987.89 (38.8%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Education | $1,557 | 27 | 61.2% |
| Food and Beverage | $987.89 | 48 | 38.8% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Astellas Pharma US Inc | $1,761 | 39 | $0 (2024) |
| PFIZER INC. | $352.49 | 16 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $111.63 | 4 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $103.23 | 6 | $0 (2022) |
| SANOFI-AVENTIS U.S. LLC | $76.99 | 1 | $0 (2021) |
| Merck Sharp & Dohme Corporation | $39.72 | 3 | $0 (2018) |
| GlaxoSmithKline, LLC. | $33.38 | 2 | $0 (2018) |
| Novartis Pharmaceuticals Corporation | $20.84 | 1 | $0 (2018) |
| Genentech USA, Inc. | $18.22 | 1 | $0 (2021) |
| Incyte Corporation | $16.14 | 1 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $260.87 | 5 | Astellas Pharma US Inc ($240.30) |
| 2023 | $59.65 | 3 | Astellas Pharma US Inc ($46.28) |
| 2022 | $108.36 | 6 | E.R. Squibb & Sons, L.L.C. ($36.94) |
| 2021 | $668.16 | 20 | Astellas Pharma US Inc ($362.74) |
| 2020 | $380.03 | 12 | Astellas Pharma US Inc ($305.72) |
| 2019 | $358.32 | 12 | Astellas Pharma US Inc ($294.70) |
| 2018 | $574.06 | 13 | Astellas Pharma US Inc ($379.60) |
| 2017 | $135.72 | 4 | Astellas Pharma US Inc ($107.54) |
All Payment Transactions
75 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/13/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $20.57 | General |
| Category: Respiratory | ||||||
| 05/29/2024 | Astellas Pharma US Inc | Xtandi (Drug) | Food and Beverage | In-kind items and services | $22.22 | General |
| Category: Oncology | ||||||
| 01/23/2024 | Astellas Pharma US Inc | — | Education | In-kind items and services | $98.00 | General |
| 01/23/2024 | Astellas Pharma US Inc | — | Education | In-kind items and services | $87.99 | General |
| 01/04/2024 | Astellas Pharma US Inc | Xtandi (Drug) | Food and Beverage | In-kind items and services | $32.09 | General |
| Category: Oncology | ||||||
| 06/21/2023 | PFIZER INC. | IBRANCE (Drug) | Food and Beverage | In-kind items and services | $13.37 | General |
| Category: ONCOLOGY | ||||||
| 03/23/2023 | Astellas Pharma US Inc | Xtandi (Drug) | Food and Beverage | In-kind items and services | $23.50 | General |
| Category: Oncology | ||||||
| 01/18/2023 | Astellas Pharma US Inc | Xtandi (Drug) | Food and Beverage | In-kind items and services | $22.78 | General |
| Category: Oncology | ||||||
| 10/03/2022 | Astellas Pharma US Inc | Xtandi (Drug) | Food and Beverage | In-kind items and services | $24.10 | General |
| Category: Oncology | ||||||
| 09/21/2022 | PFIZER INC. | IBRANCE (Drug), PAXLOVID | Food and Beverage | In-kind items and services | $16.64 | General |
| Category: ONCOLOGY | ||||||
| 08/18/2022 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $16.14 | General |
| Category: Hematology/Oncology | ||||||
| 06/22/2022 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $14.68 | General |
| Category: Oncology | ||||||
| 02/24/2022 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $22.26 | General |
| Category: Cardiovascular | ||||||
| 02/16/2022 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $14.54 | General |
| Category: Respiratory | ||||||
| 12/06/2021 | Astellas Pharma US Inc | — | Education | In-kind items and services | $99.00 | General |
| 12/06/2021 | Astellas Pharma US Inc | — | Education | In-kind items and services | $79.99 | General |
| 12/06/2021 | Astellas Pharma US Inc | XTANDI (Drug) | Food and Beverage | In-kind items and services | $22.50 | General |
| Category: ONCOLOGY | ||||||
| 11/19/2021 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $14.24 | General |
| Category: Oncology | ||||||
| 11/16/2021 | PFIZER INC. | INLYTA (Drug) | Education | In-kind items and services | $7.60 | General |
| Category: ONCOLOGY | ||||||
| 11/03/2021 | Astellas Pharma US Inc | XTANDI (Drug) | Food and Beverage | In-kind items and services | $23.14 | General |
| Category: ONCOLOGY | ||||||
| 10/26/2021 | SANOFI-AVENTIS U.S. LLC | ELITEK (Biological) | Education | In-kind items and services | $76.99 | General |
| Category: Oncology | ||||||
| 10/06/2021 | Astellas Pharma US Inc | XTANDI (Drug) | Food and Beverage | In-kind items and services | $22.74 | General |
| Category: ONCOLOGY | ||||||
| 09/15/2021 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $16.39 | General |
| Category: Respiratory | ||||||
| 09/03/2021 | PFIZER INC. | INLYTA (Drug) | Education | In-kind items and services | $124.40 | General |
| Category: ONCOLOGY | ||||||
| 09/03/2021 | PFIZER INC. | INLYTA (Drug) | Education | In-kind items and services | $8.20 | General |
| Category: ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 302 | 1,250 | $137,955 | $74,221 |
| 2022 | 4 | 334 | 1,320 | $146,026 | $77,839 |
| 2021 | 4 | 330 | 1,331 | $136,047 | $78,748 |
| 2020 | 5 | 283 | 1,168 | $107,760 | $59,472 |
Total Patients
1,249
Total Services
5,069
Medicare Billing
$290,281
Procedure Codes
21
All Medicare Procedures & Services
21 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 166 | 949 | $109,135 | $59,991 | 55.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 17 | 178 | $20,470 | $8,661 | 42.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 16 | 16 | $3,265 | $2,060 | 63.1% |
| 90674 | Influenza vaccine, quadrivalent derived from cell cultures, preservative and antibiotic free | Office | 2023 | 52 | 54 | $2,700 | $1,808 | 67.0% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 51 | 53 | $2,385 | $1,701 | 71.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 185 | 989 | $113,735 | $61,686 | 54.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 17 | 199 | $22,885 | $9,953 | 43.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 20 | 20 | $4,086 | $2,672 | 65.4% |
| G0008 | Administration of influenza virus vaccine | Office | 2022 | 56 | 56 | $2,520 | $1,795 | 71.2% |
| 90674 | Influenza vaccine, quadrivalent derived from cell cultures, preservative and antibiotic free | Office | 2022 | 56 | 56 | $2,800 | $1,732 | 61.9% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 181 | 1,017 | $108,153 | $64,962 | 60.1% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 17 | 178 | $19,038 | $8,914 | 46.8% |
| 90674 | Vaccine for influenza derived from cell cultures for administration into muscle, 0.5 ml dosage, quadrivalent, , preservative and antibiotic free | Office | 2021 | 62 | 64 | $3,200 | $1,915 | 59.9% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 15 | 15 | $3,087 | $1,898 | 61.5% |
| G0008 | Administration of influenza virus vaccine | Office | 2021 | 55 | 57 | $2,570 | $1,059 | 41.2% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 157 | 856 | $80,669 | $46,855 | 58.1% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 17 | 203 | $19,131 | $7,751 | 40.5% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Office | 2020 | 16 | 16 | $3,274 | $1,960 | 59.9% |
| 90694 | Influenza virus vaccine, quadrivalent (aiiv4), inactivated, adjuvanted, preservative free, for injection into muscle, 0.5 ml dosage | Office | 2020 | 30 | 30 | $1,765 | $1,566 | 88.7% |
| G0008 | Administration of influenza virus vaccine | Office | 2020 | 46 | 46 | $2,070 | $843.18 | 40.7% |
| 90674 | Vaccine for influenza for administration into muscle, 0.5 ml dosage | Office | 2020 | 17 | 17 | $850.00 | $496.91 | 58.5% |
About Dr. Taying Yang, MD
Dr. Taying Yang, MD is a Hematology & Oncology healthcare provider based in Kaneohe, Hawaii. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/07/2006. The National Provider Identifier (NPI) number assigned to this provider is 1477585594.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Taying Yang, MD has received a total of $2,545 in payments from pharmaceutical and medical device companies, with $260.87 received in 2024. These payments were reported across 75 transactions from 11 companies. The most common payment nature is "Education" ($1,557).
As a Medicare-enrolled provider, Yang has provided services to 1,249 Medicare beneficiaries, totaling 5,069 services with total Medicare billing of $290,281. Data is available for 4 years (2020–2023), covering 21 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Kaneohe, HI
- Active Since 07/07/2006
- Last Updated 06/25/2010
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1477585594
Products in Payments
- XTANDI (Drug) $316.14
- INLYTA (Drug) $166.88
- Xtandi (Drug) $132.28
- XOSPATA (Drug) $99.75
- IBRANCE (Drug) $95.55
- OPDIVO (Biological) $80.97
- ELITEK (Biological) $76.99
- IMFINZI (Drug) $60.13
- LORBRENA (Drug) $33.15
- BREZTRI (Drug) $30.93
- KEYTRUDA (Biological) $24.31
- ELIQUIS (Drug) $22.26
- PROMACTA (Drug) $20.84
- AIRSUPRA (Drug) $20.57
- Alecensa (Biological) $18.22
- BREO (Drug) $16.75
- ADVAIR (Drug) $16.63
- JAKAFI (Drug) $16.14
- VIZIMPRO (Drug) $15.32
- BAVENCIO (Drug) $14.65
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.